Valrubicin is an anthracycline used intravesically in the treatment of BCG-resistant bladder carcinoma. Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR.
- Mechanism
- Curator reviewed
Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II.
- Primary indication
- For the treatment of cancer of the bladder.Curator reviewed · 1 structured indication
- Formula / weight
- C34H36F3NO13 · 723.651 g/mol (avg)
- First approval
- Canada, 2009 · United States, 1998
- Code names
- AD-32 · NSC-246131
- Brand names
Resolves to
ZOCKGBMQLCSHFP-KQRAQHLDSA-NSMILES[H][C@@]1(C[C@@](O)(CC2=C(O)C3=C(C(O)=C12)C(=O)C1=C(OC)C=CC=C1C3=O)C(=O)COC(=O)CCCC)O[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1What you can answer from here — as of September 12, 2026
Which drugs share a target with Valrubicin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account